Introductions {#S0001}
=============

The onset of inflammatory bowel disease (IBD) peaks within the second decade of life, with approximately 20--35% of patients diagnosed in the paediatric age group \[[@CIT0001], [@CIT0002]\]. Inflammatory bowel disease includes ulcerative colitis (UC) and Crohn\'s disease (CD). According to recent reports \[[@CIT0003], [@CIT0004]\] the incidence of paediatric CD has increased, although the incidence of UC has remained stable \[[@CIT0005]\]. Not only is the number of patients increasing but there is also data indicating onset of IBD within the first years of life \[[@CIT0006], [@CIT0007]\]. Inflammatory bowel disease of very early onset includes, apart from UC and CD, a relatively high proportion of indeterminate colitis (IC). Paediatric onset IBD has unique phenotypic heterogeneity, responses to therapy, and prognosis. The manifestation of early-onset IBD has a very severe course and guarded prognosis with life-threatening symptoms \[[@CIT0008], [@CIT0009]\]. Overall the disease manifestations are primarily colonic, with severe perianal disease and severe extra-gastrointestinal manifestations, and it can rapidly progress to pancolitis \[[@CIT0006]\]. Early-onset IBD is unique in its association to metabolic diseases, neutrophil defects, and immunodeficiency. Therefore, it is controversial whether this form belongs to UC and CD or is a presentation of the primary disease \[[@CIT0010]\]. The aetiology of IBD is unknown. Recent data suggest that altered immune homeostasis within the intestinal mucosa, together with phagocytic function, metabolic pathways, environmental factors, and genetic predisposition play a role in its pathology. The last factor seems to play a fundamental role in the natural history of early-onset IBD. Current data suggest mutations in genes encoding interleukin-10 receptor, IL-27, MTMR3 (essential component of autophagy), and CAPN10 (necessary for the regulation of endoplasmic reticulum stress). In addition, the roles of PSMG1, TNFRSF6B, ZMIZ1, and SMAD3 are also discussed in relation to abnormal protein degradation and secondary immune response \[[@CIT0011]\].

Inflammatory bowel disease in children younger than five years has a distinct phenotype and should be considered as a specific entity. There are only a few reports analysing the outcome of this paediatric subgroup. Longitudinal studies are needed to determine the clinical implications of early-onset IBD.

Aim {#S0002}
===

The aim of this study was to determine the characteristics and clinical course of children with early-onset IBD.

Material and methods {#S0003}
====================

We performed a retrospective database analysis of 47 infants less than 5 years old, diagnosed with IBD at 6 paediatric centres in Poland: the Children\'s Memorial Health Institute, Warsaw; and hospitals in Bialystok, Szczecin, Rzeszow, Gdansk, and Wroclaw. Patient demographics, including age, sex, and age at disease onset, were tallied. Disease location was identified on the basis of a review of all endoscopic, colonoscopic, histopathological, and radiologic records. The Montreal Classification was used to classify the location of a disease.

All possible complications were reported. Patients were administered different medications such as prednisolone, azathioprine, 6-mercaptopurine, methotrexate, and antibiotics. Biological agents and surgery were also included. The efficacy of the applied treatment was assessed. Patients were followed up clinically to determine the extent of disease progression on the basis of the initial diagnosis of IBD.

Results {#S0004}
=======

Among 47 children registered in the database 23 (49%) had a diagnosis of CD, 16 (34%) had UC, and 8 (17%) had IC. The mean age at diagnosis was 28.5 ±27.5 months; 57.4% were male. One (2.12%) patient had limited caecal disease (L1), 20 (42.5%) had colon involvement (L2), and 25 (53.2%) had ileocolonic location (L3), whether CD, UC, or IC. Upper gastrointestinal tract involvement was found in seven CD patients, but it was not isolated upper disease (L4) as they had simultaneously either colonic or ileocolonic lesions. In 1 (2.15%) UC patient extra-intestinal manifestation of the disease was a presenting symptom. In this case the diagnosis of IBD was established on the base of a histopathological examination of the biopsy taken during endoscopy performed as part of a differential diagnosis. [Table I](#T0001){ref-type="table"} presents demographic characteristic of 47 patients with EO-IBD, and [Figure 1](#F0001){ref-type="fig"} presents the exact location of the disease in CD, UC, and IC patients individually. Anaemia, the most common complication, was detected in 30 (63.8%) objects. Three (6.4%) patients younger than 3 years of age developed strictures; 2 (4.2%) patients younger than 1 year of age developed abscess; 1 (4.2%) patient at the age of 4 months developed fistula. Most children were treated with mesalamine (93.6%) and/or steroids (59.6%) either orally or intravenously. Five CD patients younger than 3 years of age were administered infliximab and 4 of them had to undergo surgery. [Figure 2](#F0002){ref-type="fig"} presents the types and incidences of administered treatments. Overall, response to the treatment was positive in most cases; the average number of flare-ups was one, except from 4 of the CD patients who were treated with therapy including biological agents and operation.

![Location of the disease according to Montreal Classification](PG-11-25352-g001){#F0001}

![Types and incidence of administered treatments\
Most often applied medication -- mesalamine (44 patients). Steroids -- 28 children (with/or without mesalamine). Infliximab -- 5 patients. Surgery -- 4 children (all of them had previously received infliximab).](PG-11-25352-g002){#F0002}

###### 

Demographic characteristics of 47 children with early clinical manifestation of inflammatory bowel disease

  Parameter                          CD patients              UC patients              IC patients
  ---------------------------------- ------------------------ ------------------------ ------------------------
  Number of patients (*n*)           23/47                    16/47                    8/16
  Male                               11/23                    10/16                    5/8
  Mean age at diagnosis \[months\]   19.7 (from 4 up to 56)   19.6 (from 1 up to 56)   11.7 (from 1 up to 32)
  Mean age at diagnosis \[months\]                            19.6 (from 1 up to 56)   
  Complications:                                                                       
   None                              6/23                     9/16                     2/8
   Anaemia                           17/23                    7/16                     6/8
   Strictures                        3/23                     0/16                     0/8
   Fistula                           1/23                     0/16                     0/8
   Abscess                           1/23                     1/16                     0/8

Discussion {#S0005}
==========

The incidence and prevalence of IBD has risen during the last few decades even in young children. Although rare, IBD can begin in infancy \[[@CIT0009]\]. Clinical data on very early-onset IBD are sparse as this group represents a small subset of paediatric IBD patients. The aim of our study was to determine the characteristics and clinical course of IBD in children younger than 5 years old. Some studies suggest that early-onset IBD has a distinct phenotype and should be considered as a specific entity \[[@CIT0006], [@CIT0010]\]. The prevalence of IC in this paediatric subgroup is higher than that observed in older children and adults. In our database the diagnosis of CD prevailed; however, there were eight (17%) infants with IC, all of them younger than 3 years of age. Diagnosis of IBD in this age group is particularly difficult. The differential diagnoses are infectious and allergic colitis, which are the major causes of infantile colitis. Rare conditions such as immune defects (e.g. septic granulomatosis) or GSD type 1b can mimic IBD \[[@CIT0012]\]. None of these were ruled out in our patients.

Some studies also suggested that IBD in infants follows a more severe course than in older patients, whereas other studies did not imply a similar poor prognosis \[[@CIT0006], [@CIT0009], [@CIT0013], [@CIT0014]\]. Overall, the disease manifestations are primarily colonic and rapidly progress to pancolitis. In our study almost all of the 47 children had colitis, except 1 patient who presented only extra-intestinal manifestation. This colonic location of the disease in our patients was consistent with reports of Heymen *et al*. \[[@CIT0009]\] and Mamula *et al*. \[[@CIT0015]\]. All of their patients also had colitis. We classified a disease location according to Paris Classification, which is a paediatric modification of Montreal Classification \[[@CIT0016]\]. Only 17 (36.2%) patients had isolated colonic disease (L2), while 8 (17%) had ileocolonic disease (L3), and 20 (42.5%) had pancolitis. It may be caused by the fact that very early-onset IBD rapidly progresses to pancolitis. Some studies report that IBD in infants has a very severe course with extra-gastrointestinal symptoms and guarded prognosis with life-threatening signs and needs an aggressive therapeutic approach \[[@CIT0010]\]. In our study only one UC patient younger than 3 years of age had extra-gastrointestinal symptoms. In this case the diagnosis of IBD was established due to an endoscopy performed during the diagnostic process of presented symptoms. In 17 (36.2%) children no complications were observed, and the most common complication was anaemia, which was detected in 30 (63.8%) patients. Three (6.4%) patients younger than 3 years of age developed strictures, 2 (4.2%) younger than one year of age developed abscess, and 1 (4.2%) infant at the age of 4 months developed fistula. These were patients with severe and refractory conditions, who needed an aggressive therapeutic approach including a biological agent (infliximab). Four of them had to undergo surgery. Dokucu *et al*. \[[@CIT0017]\] observed that the need for surgery was markedly higher and earlier in this specific paediatric subgroup. Overall, among 47 children, the course of the disease was severe or moderate. Almost all of our patients received mesalamine (93.6%) and/or multiple immunosuppressive drugs (most often steroids either orally or intravenously). Thirty-eight (81%) patients had a history of using antibiotics. Altered interaction between the normal gut flora and the intestinal mucosa is a major triggering factor for IBD \[[@CIT0002], [@CIT0007], [@CIT0018]\], and some studies indicate a link between antibiotic use and the development of IBD \[[@CIT0019], [@CIT0020]\]. Moreover, IBD in infancy can be associated with metabolic diseases, neutrophil defects, and immunodeficiency states \[[@CIT0010]\], but it is still not known whether those patients have an immunological disorder or genetic basis of the disease.

Early-onset IBD has a distinct phenotype and presents a unique opportunity to study the impact of immunological status, gut microflora, metabolic pathways, and environmental factors on the genetic predisposition and the natural history of IBD.

Conclusions {#S0006}
===========

Inflammatory bowel disease in children younger than 5 years includes UC and CD and a relatively high proportion of IC. In early-onset IBD severe and moderate course of the disease is apparent. Pathological changes are present mainly in the large intestine and only in single cases in the upper part of the alimentary tract and jejunum, and the disease rapidly progresses to pancolitis. Longitudinal studies are needed to determine the clinical implications of this paediatric IBD subgroup.
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